Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255 ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...